Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHARISMA trial of neoadjuvant chemotherapy plus surgery versus surgery alone for high-risk resectable colorectal liver metastases
NL-OMON27498Phase 3Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Oct 2014
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin in colorectal cancer (CRC) and colorectal cancer liver metastasis (CRLM), sponsored by Erasmus MC. Primary endpoint: Overall survival. Started Oct 2014; status: active, not recruiting.
02
Drugs
oxaliplatin
03
Conditions
colorectal cancer (CRC)colorectal cancer liver metastasis (CRLM)
Beyond the preview
Go deeper on NL-OMON27498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27498.